Get notified when VANI files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVivani shifts lead program to semaglutide, raises $9.9M, extends runway to mid-2027
Filed May 13, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 13, 2025 · ~2 min read
Key Changes
-
high
Lead program changed from NPM-115 (exenatide implant) to NPM-139 (semaglutide implant) for weight management, with new preclinical data showing 20% weight loss maintained for one year in rats.
MD&A: Lead Program verify on EDGAR → -
high
Raised $9.9M in Q1 2026 through two concurrent equity offerings and tranche closings under 2025 agreements, extending cash runway from 'at least twelve months' to mid-2027.
MD&A: Capital Raises verify on EDGAR → -
high
New Oppenheimer lawsuit seeks $1.625M in damages over failed Pixium business combination; breach-of-contract claim survived motion to dismiss, now in discovery with appeals filed by both parties.
Legal Proceedings verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ISNR 10-Q) is open in full — no account needed.
Partner
Trade VANI commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify